EMA/265315/2010

European Medicines Agency decision
P/69/2010

of 4 May 2010


Only the English text is authentic.
European Medicines Agency decision
P/69/2010

of 4 May 2010


The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency2,

Having regard to the application submitted by Mundipharma Research Ltd. on 11 December 2009 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 March 2010 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee has given an opinion on the granting of a product specific waiver,

(2) It is therefore appropriate to adopt a decision granting a waiver.

---

Has adopted this decision:

**Article 1**

A waiver for forodesine hydrochloride, hard capsule, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 2**

This decision is addressed to Mundipharma Research Ltd., Cambridge Science Park, Milton Road, Cambridge, CB4 0AB, United Kingdom.

Done at London, 4 May 2010

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)
Opinion of the Paediatric Committee on the granting of a product-specific waiver
EMEA-000785-PIP01-09

Scope of the application

Active substance(s):
Forodesine hydrochloride

Condition(s):
Cutaneous T-cell lymphoma (CTCL)

Pharmaceutical form(s):
Hard capsule

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
Mundipharma Research Ltd.

Basis for opinion


The procedure started on 21 January 2010.
Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
   - to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

   The Norwegian Paediatric Committee member(s) agree(s) with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 19 March 2010

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)
Annex I

Grounds for the granting of the waiver
1. GROUNDS FOR THE GRANTING OF THE WAIVER

1.1. Condition

Cutaneous T-cell lymphoma (CTCL)

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age
- for hard capsule for oral use
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.